Ingested arsenic, keratoses, and bladder cancer.
A cohort of 478 patients treated with Fowler's solution (potassium arsenite) in Lancashire, England, during the period 1945-1969 and previously followed until January 1, 1980, was followed for an additional 11 years. A significant excess of bladder cancer mortality occurred (observed/expected ratio = 5/1.6; p = 0.05). No excess was found for other causes of death. In a subcohort of 142 patients examined for signs of arsenicism around 1970, all 11 subsequent cancer deaths occurred in those with signs of arsenicism (p = 0.0009).
Cuzick
J
J
Department of Mathematics, Statistics, and Epidemiology, Imperial Cancer Research Fund, Lincoln's Inn Fields, London, England.
Sasieni
P
P
Evans
S
S
D001151:Arsenic / Q000009:adverse effects*; D020261:Arsenic Poisoning; D018053:Arsenites; D002318:Cardiovascular Diseases / Q000401:mortality; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007642:Keratosis / Q000139:chemically induced*; D008297:Male; D009369:Neoplasms / Q000139:chemically induced / Q000401:mortality; D011188:Potassium / Q000009:adverse effects*; D017680:Potassium Compounds; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000401:mortality*
D018053:Arsenites; D017680:Potassium Compounds; C009003:potassium arsenite solution; D001151:Arsenic; D011188:Potassium